nutra pharm cp - NPHC

NPHC

Close Chg Chg %
0.00 0.00 0.00%

Closed Market

0.00

0.00 (0.00%)

Volume: 101.88K

Last Updated:

Dec 30, 2025, 2:19 PM EDT

Company Overview: nutra pharm cp - NPHC

NPHC Key Data

Open

$0.00

Day Range

0.00 - 0.00

52 Week Range

0.00 - 0.01

Market Cap

$0.00

Shares Outstanding

7.10B

Public Float

7.03B

Beta

65.47

Rev. Per Employee

N/A

P/E Ratio

N/A

EPS

-$0.00

Yield

0.00%

Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

309.81K

 

NPHC Performance

1 Week
 
-90.00%
 
1 Month
 
-80.00%
 
3 Months
 
0.00%
 
1 Year
 
0.00%
 
5 Years
 
N/A
 

NPHC Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 1
Full Ratings ➔

About nutra pharm cp - NPHC

Nutra Pharma Corp. operates as a bio pharmaceutical company. The firm engages in the acquisition, licensing and commercialization of pharmaceutical products and technologies & homeopathic and ethical drugs for the management of pain, neurological disorders, autoimmune and infectious diseases. Its products are Cobroxin, which is used for an over-the-counter pain reliever designed to treat moderate to severe chronic pain and Nyloxin Extra Strength, which is used for stronger versions of Cobroxin. The company was founded on February 1, 2000 and is headquartered in Boca Raton, FL.

NPHC At a Glance

Nutra Pharma Corp.
6400 Park of Commerce Blvd
Boca Raton, Florida 33487
Phone 1-954-509-0911 Revenue 594.88K
Industry Internet Retail Net Income -1,393,356.00
Sector Retail Trade 2023 Sales Growth 35.732%
Fiscal Year-end 12 / 2024 Employees 6
View SEC Filings

NPHC Valuation

P/E Current N/A
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) N/A
Price to Sales Ratio 1.279
Price to Book Ratio N/A
Price to Cash Flow Ratio N/A
Enterprise Value to EBITDA -12.694
Enterprise Value to Sales 16.887
Total Debt to Enterprise Value 0.927

NPHC Efficiency

Revenue/Employee 99,146.667
Income Per Employee -232,226.00
Receivables Turnover 2.594
Total Asset Turnover 0.853

NPHC Liquidity

Current Ratio 0.022
Quick Ratio 0.021
Cash Ratio 0.002

NPHC Profitability

Gross Margin 53.629
Operating Margin -149.102
Pretax Margin -234.225
Net Margin -234.225
Return on Assets -199.72
Return on Equity N/A
Return on Total Capital 31.241
Return on Invested Capital N/A

NPHC Capital Structure

Total Debt to Total Equity N/A
Total Debt to Total Capital -208.702
Total Debt to Total Assets 1,453.512
Long-Term Debt to Equity N/A
Long-Term Debt to Total Capital -5.315
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Nutra Pharm Cp - NPHC

Collapse All in section
All values USD millions. 2020 2021 2022 2023 5-year trend
Sales/Revenue
51.90K 97.73K 438.27K 594.88K
Sales Growth
-50.29% +88.32% +348.43% +35.73%
Cost of Goods Sold (COGS) incl D&A
100.50K 143.57K 283.06K 275.85K
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
67.35K 63.38K 116.49K 95.62K
Depreciation
67.35K 63.38K 116.49K 95.62K
Amortization of Intangibles
- - - -
-
COGS Growth
-29.88% +42.85% +97.16% -2.55%
Gross Income
(48.60K) (45.83K) 155.21K 319.03K
Gross Income Growth
-24.85% +5.70% +438.64% +105.54%
Gross Profit Margin
-93.65% -46.90% +35.41% +53.63%
2020 2021 2022 2023 5-year trend
SG&A Expense
876.34K 1.94M 2.06M 1.21M
Research & Development
- - - -
-
Other SG&A
876.34K 1.94M 2.06M 1.21M
SGA Growth
-26.42% +121.67% +6.18% -41.53%
Other Operating Expense
- - - -
-
Unusual Expense
(491.94K) 10.61M (10.86M) 179.68K
EBIT after Unusual Expense
(433.01K) (12.60M) 8.95M (1.07M)
Non Operating Income/Expense
- - 16.21K 73.06K
-
Non-Operating Interest Income
- - 16.21K 73.06K
-
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
336.17K 495.68K 791.48K 399.76K
Interest Expense Growth
+28.30% +47.45% +59.68% -49.49%
Gross Interest Expense
336.17K 495.68K 791.48K 399.76K
Interest Capitalized
- - - -
-
Pretax Income
(769.18K) (13.10M) 8.18M (1.39M)
Pretax Income Growth
+88.33% -1,602.52% +162.44% -117.04%
Pretax Margin
-1,482.14% -13,399.01% +1,865.70% -234.22%
Income Tax
- - - -
-
Income Tax - Current - Domestic
- - - -
-
Income Tax - Current - Foreign
- - - -
-
Income Tax - Deferred - Domestic
- - - -
-
Income Tax - Deferred - Foreign
- - - -
-
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
(769.18K) (13.10M) 8.18M (1.39M)
Minority Interest Expense
- - - -
-
Net Income
(769.18K) (13.10M) 8.18M (1.39M)
Net Income Growth
+88.33% -1,602.52% +162.44% -117.04%
Net Margin Growth
-1,482.14% -13,399.01% +1,865.70% -234.22%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
(769.18K) (13.10M) 8.18M (1.39M)
Preferred Dividends
- - - -
-
Net Income Available to Common
(769.18K) (13.10M) 8.18M (1.39M)
EPS (Basic)
-0.0001 -0.0018 0.0011 -0.0002
EPS (Basic) Growth
+92.86% -1,700.00% +161.11% -118.18%
Basic Shares Outstanding
6.61B 7.23B 7.50B 7.61B
EPS (Diluted)
-0.0001 -0.0018 0.0004 -0.0002
EPS (Diluted) Growth
+92.86% -1,700.00% +122.22% -150.00%
Diluted Shares Outstanding
6.61B 7.23B 19.10B 7.61B
EBITDA
(857.60K) (1.93M) (1.79M) (791.36K)
EBITDA Growth
+25.59% -124.47% +6.97% +55.81%
EBITDA Margin
-1,652.50% -1,969.67% -408.63% -133.03%

Nutra Pharm Cp in the News